Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 3

1(20.0%)

5Total

N/A(4)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03720223Phase 3Completed

Liposomal Bupivacaine To Control Post-Operative Pain Following BMG

Role: lead

NCT04599283Not ApplicableCompleted

BE Technologies Mobile Uroflowmetry Validation Study

Role: collaborator

NCT02122341Not ApplicableTerminated

Clinical Evaluation of BackStop in Patients Undergoing Ureteroscopic Lithotripsy

Role: collaborator

NCT01344564Not ApplicableCompleted

Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide

Role: lead

NCT00274417Not ApplicableUnknown

Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP)

Role: lead

All 5 trials loaded